Sangamo Therapeutics (NASDAQ:SGMO) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report published on Thursday,Benzinga reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock.

SGMO has been the topic of a number of other reports. Jefferies Financial Group dropped their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday. Barclays lifted their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Wells Fargo & Company decreased their price objective on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a report on Tuesday. StockNews.com lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Finally, Truist Financial raised Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research note on Friday, December 13th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Sangamo Therapeutics Stock Up 10.8 %

SGMO opened at $1.13 on Thursday. Sangamo Therapeutics has a 52-week low of $0.30 and a 52-week high of $3.18. The company has a market cap of $235.77 million, a P/E ratio of -1.51 and a beta of 1.15. The company has a 50 day moving average of $2.14 and a two-hundred day moving average of $1.22.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. During the same period in the prior year, the company posted ($0.34) EPS. Research analysts anticipate that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of Sangamo Therapeutics during the 3rd quarter worth about $150,000. Geode Capital Management LLC grew its holdings in shares of Sangamo Therapeutics by 14.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after purchasing an additional 272,123 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 64,981 shares in the last quarter. State Street Corp raised its stake in Sangamo Therapeutics by 28.0% in the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock valued at $576,000 after purchasing an additional 145,400 shares in the last quarter. Finally, FMR LLC lifted its position in Sangamo Therapeutics by 16.5% during the third quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock worth $471,000 after purchasing an additional 77,032 shares during the period. 56.93% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.